135 related articles for article (PubMed ID: 34913222)
1. Potential biomarkers identified by tandem mass tags based quantitative proteomics for diagnosis and classification of Guillain-Barré syndrome.
Ding Y; Shi Y; Wang L; Li G; Osman RA; Sun J; Qian L; Zheng G; Zhang G
Eur J Neurol; 2022 Apr; 29(4):1155-1164. PubMed ID: 34913222
[TBL] [Abstract][Full Text] [Related]
2. Altered cerebrospinal fluid index of prealbumin, fibrinogen, and haptoglobin in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.
Zhang HL; Zhang XM; Mao XJ; Deng H; Li HF; Press R; Fredrikson S; Zhu J
Acta Neurol Scand; 2012 Feb; 125(2):129-35. PubMed ID: 21434877
[TBL] [Abstract][Full Text] [Related]
3. Elevated haptoglobin level of cerebrospinal fluid in Guillain-Barré syndrome revealed by proteomics analysis.
Chang KH; Lyu RK; Tseng MY; Ro LS; Wu YR; Chang HS; Hsu WC; Kuo HC; Huang CC; Chu CC; Hsieh SY; Chen CM
Proteomics Clin Appl; 2007 May; 1(5):467-75. PubMed ID: 21136698
[TBL] [Abstract][Full Text] [Related]
4. Quantitative proteomics reveals Piccolo as a candidate serological correlate of recovery from Guillain-Barré syndrome.
Mateos-Hernández L; Villar M; Doncel-Pérez E; Trevisan-Herraz M; García-Forcada Á; Ganuza FR; Vázquez J; de la Fuente J
Oncotarget; 2016 Nov; 7(46):74582-74591. PubMed ID: 27776345
[TBL] [Abstract][Full Text] [Related]
5. Identification of potential biomarkers for neuromyelitis optica by quantitative proteomics.
Ding Y; Chen Y; Sun J; Shi Y; Li G; Luan X; Wang S; Li X; Jiang W; Wang L; Zhang G
Ann Clin Transl Neurol; 2024 May; 11(5):1184-1196. PubMed ID: 38425144
[TBL] [Abstract][Full Text] [Related]
6. Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with GBS and CIDP using a proximity extension assay.
Kmezic I; Gustafsson R; Fink K; Svenningsson A; Samuelsson K; Ingre C; Olsson T; Hansson M; Kockum I; Adzemovic MZ; Press R
Front Immunol; 2023; 14():1241199. PubMed ID: 38077366
[TBL] [Abstract][Full Text] [Related]
7. IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barré syndrome.
Li S; Yu M; Li H; Zhang H; Jiang Y
Mediators Inflamm; 2012; 2012():260473. PubMed ID: 23091305
[TBL] [Abstract][Full Text] [Related]
8. Comparative proteomics analysis of cerebrospinal fluid of patients with Guillain-Barré syndrome.
Yang YR; Liu SL; Qin ZY; Liu FJ; Qin YJ; Bai SM; Chen ZY
Cell Mol Neurobiol; 2008 Aug; 28(5):737-44. PubMed ID: 18343991
[TBL] [Abstract][Full Text] [Related]
9. Identification of CSF biomarkers by proteomics in Guillain-Barré syndrome.
Li P; Wang S; Zhang R; Pei J; Chen L; Cao Y; Zhang H; Yang G
Exp Ther Med; 2018 Jun; 15(6):5177-5182. PubMed ID: 29904402
[TBL] [Abstract][Full Text] [Related]
10. Aberrated levels of cerebrospinal fluid chemokines in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.
Press R; Pashenkov M; Jin JP; Link H
J Clin Immunol; 2003 Jul; 23(4):259-67. PubMed ID: 12959218
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid findings in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathies.
Illes Z; Blaabjerg M
Handb Clin Neurol; 2017; 146():125-138. PubMed ID: 29110767
[TBL] [Abstract][Full Text] [Related]
12. Intrathecal anti-alphaB-crystallin IgG antibody responses: potential inflammatory markers in Guillain-Barré syndrome.
Wanschitz J; Ehling R; Löscher WN; Künz B; Deisenhammer F; Kuhle J; Budka H; Reindl M; Berger T
J Neurol; 2008 Jun; 255(6):917-24. PubMed ID: 18712293
[TBL] [Abstract][Full Text] [Related]
13. The analysis of serum lipids profile in Guillain-Barre syndrome.
Wang L; Ding Y; Liu J; Zheng G; Li S; Jiang W; Chen K; Luan X; Chen Y; Wang S; Zhang G
Front Immunol; 2023; 14():1301577. PubMed ID: 38143756
[TBL] [Abstract][Full Text] [Related]
14. Proteomic identification of potential protein markers in cerebrospinal fluid of GBS patients.
Jin T; Hu LS; Chang M; Wu J; Winblad B; Zhu J
Eur J Neurol; 2007 May; 14(5):563-8. PubMed ID: 17437617
[TBL] [Abstract][Full Text] [Related]
15. Elevated levels of S100B, tau and pNFH in cerebrospinal fluid are correlated with subtypes of Guillain-Barré syndrome.
Wang XK; Zhang HL; Meng FH; Chang M; Wang YZ; Jin T; Mix E; Zhu J
Neurol Sci; 2013 May; 34(5):655-61. PubMed ID: 22526766
[TBL] [Abstract][Full Text] [Related]
16. Altered serum levels of IL-36 cytokines (IL-36α, IL-36β, IL-36γ, and IL-36Ra) and their potential roles in Guillain-Barré syndrome.
Zhao Z; Zhang R; Gao X; Li H; Liu H
Medicine (Baltimore); 2020 Dec; 99(52):e23832. PubMed ID: 33350771
[TBL] [Abstract][Full Text] [Related]
17. Increased circulating Th17 cell populations and elevated CSF osteopontin and IL-17 concentrations in patients with Guillain-Barré syndrome.
Han RK; Cheng YF; Zhou SS; Guo H; He RD; Chi LJ; Zhang LM
J Clin Immunol; 2014 Jan; 34(1):94-103. PubMed ID: 24217817
[TBL] [Abstract][Full Text] [Related]
18. Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: A pilot study.
Axelsson M; Sjögren M; Andersen O; Blennow K; Zetterberg H; Lycke J
Acta Neurol Scand; 2018 Aug; 138(2):143-150. PubMed ID: 29624650
[TBL] [Abstract][Full Text] [Related]
19. Evidence of altered Th17 pathway signatures in the cerebrospinal fluid of patients with Guillain Barré Syndrome.
Debnath M; Nagappa M; Dutta D; Talukdar PM; Subbanna M; Shivakumar V; Wahatule R; Sinha S; Bindu PS; Periyavan S; Umamaheswara Rao GS; Kumar MA; Taly AB
J Clin Neurosci; 2020 May; 75():176-180. PubMed ID: 32217048
[TBL] [Abstract][Full Text] [Related]
20. The Pathogenesis of the Demyelinating Form of Guillain-Barre Syndrome (GBS): Proteo-peptidomic and Immunological Profiling of Physiological Fluids.
Ziganshin RH; Ivanova OM; Lomakin YA; Belogurov AA; Kovalchuk SI; Azarkin IV; Arapidi GP; Anikanov NA; Shender VO; Piradov MA; Suponeva NA; Vorobyeva AA; Gabibov AG; Ivanov VT; Govorun VM
Mol Cell Proteomics; 2016 Jul; 15(7):2366-78. PubMed ID: 27143409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
